The Innovation Gap: Why Experts Say India’s Future Health Security Depends on Science and Tech Investment

Spread the Message

Read Time:4 Minute, 54 Second

NEW DELHI — Leading scientists, policy analysts, and healthcare experts are sounding an urgent alarm: India must significantly ramp up its investment in science and technology (S&T) or risk falling behind in the global race for health security and medical innovation.

At a series of high-level policy discussions this week, stakeholders emphasized that while India is often dubbed the “pharmacy of the world,” its reliance on imported active pharmaceutical ingredients (APIs) and medical devices exposes a critical vulnerability. The call to action aims to shift India from a manufacturing hub to a global leader in discovery-led research, a move experts say is essential for addressing both emerging pandemics and the rising burden of non-communicable diseases (NCDs).

The Funding Frontier: A Decisive Moment

For over a decade, India’s expenditure on Research and Development (R&D) has hovered around 0.7% of its Gross Domestic Product (GDP). In contrast, nations like the United States and China invest approximately 2.8% and 2.4% respectively, while South Korea leads the pack at nearly 4.8%.

“We are at a crossroads where incremental growth is no longer sufficient,” says Dr. Arvinth Madhavan, a senior policy researcher in biotechnology (not involved in the recent government briefings). “To secure the health of 1.4 billion people, we need a quantum leap in S&T funding. This isn’t just about laboratory equipment; it’s about creating an ecosystem where a scientist can take a molecule from a petri dish to a clinical trial right here in India.”

The push for increased funding is not merely academic. It has direct implications for the cost and accessibility of healthcare. When India develops its own medical technologies, the “innovation premium” paid to multinational corporations decreases, potentially lowering out-of-pocket expenses for patients.

From “Pharmacy” to “Laboratory”

India currently supplies 20% of the world’s generic drugs by volume. However, the next frontier of medicine lies in complex biologics, gene therapy, and mRNA technology—fields that require intensive capital and long-term research horizons.

Key areas identified for immediate investment include:

Active Pharmaceutical Ingredients (APIs): Reducing dependence on foreign imports to ensure the supply chain for life-saving drugs remains uninterrupted.
Genomic Surveillance: Expanding the ability to track viral mutations and tailor treatments to the Indian genetic makeup.
Medical Device Manufacturing: Moving beyond basic supplies to high-tech imaging and diagnostic tools.

According to data from the Economic Survey of India, while the country has seen a rise in patent filings, the transition from patent to product remains slow. Experts argue that private sector participation in R&D—which currently lags behind government spending—must be incentivized through clearer regulatory pathways and tax credits.

The Human Element: Reversing the Brain Drain

A recurring theme among experts is the “human capital” crisis. Investment in technology is futile without the minds to operate it.

“High-tech infrastructure is only half the battle,” notes Dr. Sunita Rao, an oncologist and healthcare advocate. “We need to ensure that our brightest researchers have the financial support and institutional freedom to work in India. Currently, many of our best minds go abroad because the R&D infrastructure at home cannot support their ambitions.”

The proposed investment strategy includes the establishment of more “Centres of Excellence” that bridge the gap between universities and the healthcare industry, allowing for faster “bench-to-bedside” transitions.

Public Health Implications: Preparing for the Next ‘X’

The COVID-19 pandemic served as a stark proof of concept for S&T investment. India’s ability to produce the Covaxin vaccine was a result of previous, albeit modest, investments in viral research. However, public health experts warn that the next “Disease X” may be more challenging.

Beyond pandemics, India faces a “silent emergency” of NCDs like diabetes and cardiovascular disease. Modernizing S&T investment would allow for the development of low-cost, AI-driven diagnostic tools that can be deployed in rural areas where specialist doctors are scarce.

“If we can invest in local diagnostic technology, we can catch cancer at Stage 1 instead of Stage 4,” says Dr. Rao. “That is the real-world impact of a science-first budget.”

A Balanced View: The Challenges of Scaling

While the call for more funding is nearly universal, some economists urge caution. They argue that simply “throwing money” at science is not enough. India faces systemic hurdles, including bureaucratic red tape in clinical trial approvals and a lack of collaboration between the public and private sectors.

Furthermore, critics point out that while R&D is vital, it must not come at the expense of primary healthcare funding. The challenge for the government is to strike a delicate balance: funding the high-tech future while still addressing basic sanitation, nutrition, and maternal health.

What This Means for You

For the average citizen, the “science and tech” debate may feel distant, but its outcomes will define the future of Indian family medicine. Increased S&T investment means:

Lower Drug Costs: Locally researched and manufactured drugs are generally more affordable.
Better Diagnostics: Faster and more accurate testing for chronic conditions.
Job Creation: A robust S&T sector creates high-value jobs for the next generation of Indians.

As the Indian government prepares its next fiscal roadmap, the voices of these experts serve as a reminder that science is not a luxury—it is the bedrock of a resilient nation.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.